Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for ...
Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 - - Company announced first wholly owned dual-pay ...
Enhertu approved in Japan as first tumour agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumours: Tokyo Tuesday, March 24, 202 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results